Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Jun 24

PMID 35744848

Authors

Dan Xu

Ya-Hui Hu

Xue Gou

Feng-Yang Li

Xi-Yu-Chen Yang

Yun-Man Li

Feng Chen

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PAH) is clinically characterized by a progressive increase in pulmonary artery pressure, followed by right ventricular hypertrophy and subsequently right heart failure. The underlying mechanism of PAH includes endothelial dysfunction and intimal smooth muscle proliferation. Numerous studies have shown that oxidative stress is critical in the pathophysiology of PAH and involves changes in reactive oxygen species (ROS), reactive nitrogen (RNS), and nitric oxide (NO) signaling pathways. Disrupted ROS and NO signaling pathways cause the proliferation of pulmonary arterial endothelial cells (PAECs) and pulmonary vascular smooth muscle cells (PASMCs), resulting in DNA damage, metabolic abnormalities, and vascular remodeling. Antioxidant treatment has become a main area of research for the treatment of PAH. This review mainly introduces oxidative stress in the pathogenesis of PAH and antioxidative therapies and explains why targeting oxidative stress is a valid strategy for PAH treatment.

Citing Articles

The role of lactate metabolism and lactylation in pulmonary arterial hypertension.

Peng T, Lu J, Zheng X, Zeng C, He Y Respir Res. 2025; 26(1):99.

PMID: 40075458 PMC: 11905457. DOI: 10.1186/s12931-025-03163-3.

Hypoxia Combined With Interleukin-17 Regulates Hypoxia-Inducible Factor-1α/Endothelial Nitric Oxide Synthase Expression in Pulmonary Artery Endothelial Cells.

Sun S, Mao J, Ding Y, Liu L, Gong J, Yang S J Cell Mol Med. 2025; 29(2):e70289.

PMID: 39823269 PMC: 11740980. DOI: 10.1111/jcmm.70289.

Exploring the pharmacological mechanisms for alleviating OSA: Adenosine A2A receptor downregulation of the PI3K/Akt/HIF‑1 pathway (Review).

Ma N, Liu P, Li N, Hu Y, Kang L Biomed Rep. 2024; 22(2):21.

PMID: 39720297 PMC: 11668141. DOI: 10.3892/br.2024.1899.

Pulmonary Arterial Hypertension and Cardioprotective Interventions.

Ojopi E, Tonon C, Okoshi K, Okoshi M Arq Bras Cardiol. 2024; 121(7):e20240445.

PMID: 39292052 PMC: 11495815. DOI: 10.36660/abc.20240445.

Noninvasive Monitoring of Severe Pulmonary Artery Hypertension in Atrial Septal Defect Patients: Role of Serum Bilirubin Combined with Uric Acid.

Zhang F, Lin D, Jin Q, Fan J, Chen D, Guan L Rev Cardiovasc Med. 2024; 25(2):50.

PMID: 39077349 PMC: 11263178. DOI: 10.31083/j.rcm2502050.

References

Dianat M, Radan M, Mard S, Sohrabi F, Saryazdi S . Contribution of reactive oxygen species via the OXR1 signaling pathway in the pathogenesis of monocrotaline-induced pulmonary arterial hypertension: The protective role of Crocin. Life Sci. 2020; 256:117848. DOI: 10.1016/j.lfs.2020.117848. View

Demarco V, Habibi J, Whaley-Connell A, Schneider R, Sowers J, Andresen B . Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol. 2009; 297(3):H1128-39. PMC: 2755976. DOI: 10.1152/ajpheart.00048.2009. View

Budas G, Boehm M, Kojonazarov B, Viswanathan G, Tian X, Veeroju S . ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2017; 197(3):373-385. DOI: 10.1164/rccm.201703-0502OC. View

Grzegorzewska A, Seta F, Han R, Czajka C, Makino K, Stawski L . Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. Sci Rep. 2017; 7:41605. PMC: 5288696. DOI: 10.1038/srep41605. View

Bourgeois A, Omura J, Habbout K, Bonnet S, Boucherat O . Pulmonary arterial hypertension: New pathophysiological insights and emerging therapeutic targets. Int J Biochem Cell Biol. 2018; 104:9-13. DOI: 10.1016/j.biocel.2018.08.015. View

Gonzalez-Candia A, Veliz M, Carrasco-Pozo C, Castillo R, Cardenas J, Ebensperger G . Antenatal melatonin modulates an enhanced antioxidant/pro-oxidant ratio in pulmonary hypertensive newborn sheep. Redox Biol. 2019; 22:101128. PMC: 6375064. DOI: 10.1016/j.redox.2019.101128. View

Ren X, Johns R, Gao W . EXPRESS: Right Heart in Pulmonary Hypertension: From Adaptation to Failure. Pulm Circ. 2019; :2045894019845611. PMC: 6681271. DOI: 10.1177/2045894019845611. View

Novelli E, Little-Ihrig L, Knupp H, Rogers N, Yao M, Baust J . Vascular TSP1-CD47 signaling promotes sickle cell-associated arterial vasculopathy and pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2019; 316(6):L1150-L1164. PMC: 6620668. DOI: 10.1152/ajplung.00302.2018. View

Boucherat O, Peterlini T, Bourgeois A, Nadeau V, Breuils-Bonnet S, Boilet-Molez S . Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2018; 198(1):90-103. PMC: 6835039. DOI: 10.1164/rccm.201708-1751OC. View

10.

Feng W, Hu Y, An N, Feng Z, Liu J, Mou J . Alginate Oligosaccharide Alleviates Monocrotaline-Induced Pulmonary Hypertension via Anti-Oxidant and Anti-Inflammation Pathways in Rats. Int Heart J. 2020; 61(1):160-168. DOI: 10.1536/ihj.19-096. View

11.

Dai Z, Zhu M, Peng Y, Jin H, Machireddy N, Qian Z . Endothelial and Smooth Muscle Cell Interaction via FoxM1 Signaling Mediates Vascular Remodeling and Pulmonary Hypertension. Am J Respir Crit Care Med. 2018; 198(6):788-802. PMC: 6222462. DOI: 10.1164/rccm.201709-1835OC. View

12.

Ranchoux B, Harvey L, Ayon R, Babicheva A, Bonnet S, Chan S . Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover Conference Series). Pulm Circ. 2017; 8(1):2045893217752912. PMC: 5798691. DOI: 10.1177/2045893217752912. View

13.

Wang D, Li H, Weir E, Xu Y, Xu D, Chen Y . Dimethylarginine dimethylaminohydrolase 1 deficiency aggravates monocrotaline-induced pulmonary oxidative stress, pulmonary arterial hypertension and right heart failure in rats. Int J Cardiol. 2019; 295:14-20. DOI: 10.1016/j.ijcard.2019.07.078. View

14.

Xue C, Senchanthisai S, Sowden M, Pang J, White R, Berk B . Endothelial-to-Mesenchymal Transition and Inflammation Play Key Roles in Cyclophilin A-Induced Pulmonary Arterial Hypertension. Hypertension. 2020; 76(4):1113-1123. PMC: 7485572. DOI: 10.1161/HYPERTENSIONAHA.119.14013. View

15.

Marushchak M, Maksiv K, Krynytska I, Dutchak O, Behosh N . The Severity of Oxidative Stress in Comorbid Chronic Obstructive Pulmonary Disease (COPD) and Hypertension: Does it Depend On ACE and AGT Gene Polymorphisms?. J Med Life. 2020; 12(4):426-434. PMC: 6993293. DOI: 10.25122/jml-2019-0108. View

16.

Mansouri Z, Dianat M, Radan M, Badavi M . Ellagic Acid Ameliorates Lung Inflammation and Heart Oxidative Stress in Elastase-Induced Emphysema Model in Rat. Inflammation. 2020; 43(3):1143-1156. DOI: 10.1007/s10753-020-01201-4. View

17.

Wu J, Pan W, Wang C, Dong H, Xing L, Hou J . HS attenuates endoplasmic reticulum stress in hypoxia-induced pulmonary artery hypertension. Biosci Rep. 2019; 39(7). PMC: 6614575. DOI: 10.1042/BSR20190304. View

18.

Fan Y, Zhang R, Jiang X, Wen L, Wu D, Liu D . The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. Cardiovasc Res. 2013; 99(3):395-403. DOI: 10.1093/cvr/cvt109. View

19.

Hoeper M, Ghofrani H, Grunig E, Klose H, Olschewski H, Rosenkranz S . Pulmonary Hypertension. Dtsch Arztebl Int. 2017; 114(5):73-84. PMC: 5331483. DOI: 10.3238/arztebl.2017.0073. View

20.

Wang X, Yang Y, Yang D, Tong G, Lv S, Lin X . Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1. J Vasc Surg. 2015; 64(5):1468-1477. DOI: 10.1016/j.jvs.2015.09.016. View